Natco Pharma Ltd is set to launch a generic version of Ozempic at a price 90% cheaper than the original manufactured by Novo Nordisk A/S, triggering a price war for weight loss drugs in India as the patent of key ingredient semaglutide is expiring.
at cost ₹Rs 1,290 per month, Natco Pharma’s multi-dose vial undercuts Novo Nordisk’s parent brand by nearly 90% as the first-of-its-kind vial format is ~70% cheaper than pen devices prevalent in this drug category. For patients with type 2 diabetes, the medicine has to be taken along with diet and exercise.
- Natco Pharma’s Semanat and Semaful vials will be available in strengths of 2mg/1.5ml, 4mg/3ml and 8mg/3ml. ₹1,290-1,750.
- The cost of the pen device will be ₹4,000, ₹4,200 more ₹₹4,500 per month for strengths 2mg/1.5ml, 4mg/3ml and 8mg/3ml respectively.
The Hyderabad-based drugmaker received approval from the Central Drugs Standard Control Organization in February 2026 to manufacture and market the generic drug. The approval covers both multi-dose vials and pen devices and was based on a clinical comparison study.
Natco Pharma is the first company to launch semaglutide, the active pharmaceutical ingredient in Ozempic, Vegovy and Monjaro, in vial form. The product will also be offered to third parties for co-marketing agreements.
Read this also Why is Generic Ozempic a Game Changer for China and India?